Revolution Medicines
PublicRevolution Medicines is now publicly traded
The data on this page reflects Revolution Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 18, 2020
Last Round
Follow-on Offering
Apr 17, 2026
Est. Valuation at Exit
$29.7B
Total Funding Raised
$2.97B
Company Overview
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Revolution Medicines Comparables
Compare Revolution Medicines with similar companies based on industry and business-model similarity.
No public comparables are available for Revolution Medicines. Request access to learn about comparables coverage.
Request accessRevolution Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Apr 17, 2026 | ||||
| Convertible Debt | Apr 17, 2026 | ||||
| Corporate Funding | Jun 24, 2025 | ||||
| IPO | Feb 18, 2020 | ||||
| Series C | Jul 9, 2019 | ||||
Series B | Apr 24, 2018 |
Key People
Founding team and executive leadership
Revolution Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series C, Series A Extension, Series B |
| Deerfield Management | Series C |
| Boxer Capital | Series C |
| Guggenheim Securities | IPO |
| Cormorant Asset Management | Series C |
| Fidelity Management & Research Company | Series C |
| Royalty Pharma | Corporate Funding |
Revolution Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access